Dynamic Changes and Clinical Significance of Plasma Catestatin in Patients with ST Segment Elevation Myocardial Infarction
WANG Jie,MENG Lei,DING Wen-hui,LIU Lin,YE Xiao-jin,HAN Ping
DOI: https://doi.org/10.3969/j.issn.1000-3614.2013.07.009
2013-01-01
Abstract:Objective: To observe the dynamic changes and clinical significance of plasma catestatin(CST) levels in patients with ST segment elevation myocardial infarction(STEMI). Methods: There were 2 groups in our study, STEMI group, n=58 patients and Control group, n=52 healthy subjects. Plasma levels of CST were examined by ELISA on day 1, day 3, day 7 and BNP levels were measured by chemiluminescence immunoassay on day 1, day 7 after MI onset respectively. The cardiac function was evaluated by echocardiography at 1 week after MI. The clinical conditions were followed-up. Results: Plasma CST levels in STEMI group were elevated gradually on day 1, 1.00(0.66-1.50)ng/ml, day 3, 1.12(0.76-1.70) ng/ml, day 7, 1.32(0.81-1.73)ng/ml, and they were all higher than that in Control group, 0.84(0.56-1.17) ng/ml, P0.05. Plasma CST levels were higher on day 1 and day 7 in MI patients with left ventricular systolic dysfunction(LVSD) defined as LVEF ≤ 50% and P0.05. The areas under the ROC curve(AUC) for plasma CST levels on day 1 and day 7 in eualuating LVSD were 0.69(95%CI 0.55-0.83, P0.05) and 0.71(95%CI 0.57-0.84, P0.01). The AUC for plasma BNP levels on day 1 and day 7 were 0.58(95%CI 0.42-0.74, P0.05) and 0.85(95%CI 0.75-0.94, P0.01). The follow-up study indicated that the patients with CST1.32 ng/ml on day 7 had more risk for suffering from MACE than those with CST1.32 ng/ml, P0.01.Conclusion: Plasma CST levels were elevated progressively at the acute stage of STEMI, and were related to LVSD and prognosis in those patients.